Skip to main
ELMD
ELMD logo

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. reported a significant increase in homecare revenue, which grew by 14.8% to $14.1 million, attributed to enhanced sales rep productivity and effective demand generation strategies. The company's established presence in the domestic homecare market and gradual expansion into acute care and international regions further underscore its growth potential. Although SG&A expenses rose by 17.2%, this increase reflects intentional investments in sales, marketing, and reimbursement to support ongoing growth initiatives.

Bears say

Electromed Inc. faces a challenging environment characterized by margin compression, competitive pressures, and declining sales representative productivity, which collectively hinder the company's financial performance. The significant drop in share price from a high of $35.43 to around $18 suggests a loss of investor confidence, reflecting concerns over the company's ability to sustain its market position and profitability. Additionally, the competitive landscape, along with the declining effectiveness of sales strategies, poses ongoing risks to Electromed's revenue growth and overall financial stability.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.